Karen Kaul to Combined Modality Therapy
This is a "connection" page, showing publications Karen Kaul has written about Combined Modality Therapy.
Connection Strength
0.088
-
LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. Hum Gene Ther. 2020 08; 31(15-16):863-880.
Score: 0.035
-
An Oncolytic Adenovirus Targeting Transforming Growth Factor ß Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy. Hum Gene Ther. 2019 09; 30(9):1117-1132.
Score: 0.033
-
Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a. J Am Acad Dermatol. 1993 Jul; 29(1):42-6.
Score: 0.005
-
Systemic T-cell lymphoma presenting with isolated neurological dysfunction and intraparenchymal brain lesions. Case report. J Neurosurg. 1993 Jun; 78(6):997-1001.
Score: 0.005
-
Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):198S-205S.
Score: 0.005
-
Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):203-7.
Score: 0.004